Article Text

Download PDFPDF

379 Frequency and molecular associations of KRAS mutations in gynecologic malignancies
  1. K Kilowski1,
  2. M Dietrich2,
  3. J Xiu3,
  4. S Ahmad1,
  5. M Manyam1,
  6. C Fitzsimmons1,
  7. J Kennard1,
  8. N McKenzie1,
  9. J Kendrick1,
  10. M Korn3 and
  11. R Holloway1
  1. 1AdventHealth Cancer Institute, USA
  2. 2Florida Cancer Specialists and Research Institute, USA
  3. 3Caris Life Sciences, Medical Affairs, USA


Introduction KRAS inhibitors have efficacy with non-small cell lung, pancreatic, and colon cancers. The therapeutic role in gynecologic malignancies remains investigational.

Methods Caris next-generation sequencing profiles of 859 gynecologic cancers from our institution were queried for KRAS- and BRCA-mutations, microsatellite instability (MSI), and tumor mutational burden (TMB). Wilcoxon and Fisher-Exact tests were used for comparison of molecular signatures and p<0.05 was regarded significant.

Results KRAS-mutations were present in 12.7% (33/259) uterine [endometrial cancer (EC)] and 6.7% (27/404) ovarian cancers (OC). KRAS-mutations in Type I vs. Type II EC were 20.7% (19/92) and 9.4% (13/139), respectively, and 3.6% (1/28) sarcoma. KRAS-mt OC by histologies were: papillary serous (9/306, 2.9%), endometrioid (9/23, 39.1%), mucinous (4/5, 80%), MMMT (3/38, 7.9%), clear cell (2/17, 11.8%), granulosa (0/10, 0%), and other histology (0/5, 0%) (table 1). KRAS-mutations were limited to exon 2. (for subtypes, see figures 1A and 1B). BRCA1/2-mt and KRAS-mutations were mutually exclusive in both EC and OC. KRAS-mutated EC had a greater association with MSI-H (34.8% KRAS-mt vs 16.4% KRAS-wt, p=0.0445) and TMB (median=9 mt/MB vs 8 mt/MB, p=0.0123) than KRAS-wt. No difference in TMB and MSI status was seen between KRAS-mt vs KRAS-wt OC.

Abstract 379 Figure 1

RAS sub-types in uterine (endometrial) and ovarian cancers

Abstract 379 Table 1

KRAS mutation rate by histology in uterine (endometrial) and ovarian cancers

Conclusions KRAS mutations in exon 2 are frequent in uterine and ovarian malignancies. Clinical trials evaluating subtype-specific KRAS inhibitors in uterine and ovarian tumors are warranted.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.